Compare to the P2 trial in ovarian trial, the HR (0.75) is really disappointing. The HRs in PFS for cancer drugs are generally much better than 0.7 (Zytiga, Xtandi or any other recently approved oncology drugs). Hope the HR in OS could reach 0.75 or better (P2 ovarian HR about 1.0).
As 'evil' as cancer is in general, NSCLC could be considered satan himself, so comparing PC PFS cv LC is way off balance. Anyway, on the Endo site, under events and presentations, there is a fresh PDF created Friday morning, not sure when it was actually posted to the site, probably today. FYI